Quantum Genomics Société Anonyme (ALQGC.PA)
EUR 0.07
(0.0%)
EUR 0.07
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -1.41 Million EUR | 94.74% |
| 2022 | -26.98 Million EUR | -56.85% |
| 2021 | -17.2 Million EUR | -15.44% |
| 2020 | -14.9 Million EUR | -1071.03% |
| 2019 | 1.53 Million EUR | 10111.58% |
| 2018 | -15.33 Thousand EUR | 40.73% |
| 2017 | -25.86 Thousand EUR | 99.33% |
| 2016 | -3.87 Million EUR | -47.75% |
| 2015 | -2.62 Million EUR | -162.3% |
| 2014 | -999.63 Thousand EUR | 6.6% |
| 2013 | -1.07 Million EUR | -14.32% |
| 2012 | -936.21 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | - EUR | 0.0% |
| 2023 Q4 | -539.71 Thousand EUR | 0.0% |
| 2023 FY | -3.01 Million EUR | 88.82% |
| 2023 Q2 | -1.93 Million EUR | 0.0% |
| 2022 Q4 | -18.84 Million EUR | 0.0% |
| 2022 Q2 | -10.71 Million EUR | 0.0% |
| 2022 FY | -26.98 Million EUR | -56.85% |
| 2021 FY | -17.2 Million EUR | -15.44% |
| 2021 Q4 | -6.48 Million EUR | 0.0% |
| 2021 Q2 | -9.45 Million EUR | 0.0% |
| 2020 FY | -14.9 Million EUR | -1071.03% |
| 2020 Q2 | -5.09 Million EUR | 0.0% |
| 2020 Q4 | -5.46 Million EUR | 0.0% |
| 2019 FY | 1.53 Million EUR | 10111.58% |
| 2019 Q2 | -1308.00 EUR | 0.0% |
| 2019 Q4 | -702.00 EUR | 0.0% |
| 2018 Q4 | -4165.00 EUR | 0.0% |
| 2018 FY | -15.33 Thousand EUR | 40.73% |
| 2018 Q2 | -11.16 Thousand EUR | 0.0% |
| 2017 Q2 | -14.13 Thousand EUR | 0.0% |
| 2017 FY | -25.86 Thousand EUR | 99.33% |
| 2017 Q4 | -11.73 Thousand EUR | 0.0% |
| 2016 FY | -3.87 Million EUR | -47.75% |
| 2016 Q4 | -2.33 Million EUR | 0.0% |
| 2016 Q2 | -1.96 Million EUR | 0.0% |
| 2015 Q4 | -1.75 Million EUR | 0.0% |
| 2015 FY | -2.62 Million EUR | -162.3% |
| 2015 Q2 | -870.91 Thousand EUR | 0.0% |
| 2014 Q2 | -472.08 Thousand EUR | 0.0% |
| 2014 Q4 | -527.55 Thousand EUR | 0.0% |
| 2014 FY | -999.63 Thousand EUR | 6.6% |
| 2013 Q3 | -267.56 Thousand EUR | 53.99% |
| 2013 Q1 | -267.56 Thousand EUR | -0.0% |
| 2013 Q2 | -581.55 Thousand EUR | -117.35% |
| 2013 Q4 | -484.17 Thousand EUR | -80.96% |
| 2013 FY | -1.07 Million EUR | -14.32% |
| 2012 Q3 | -234.05 Thousand EUR | -0.0% |
| 2012 Q1 | -234.05 Thousand EUR | -0.0% |
| 2012 FY | -936.21 Thousand EUR | 0.0% |
| 2012 Q4 | -267.56 Thousand EUR | -14.32% |
| 2012 Q2 | -234.05 Thousand EUR | 0.0% |
| 2011 Q4 | -234.05 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | 329.658% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 136.262% |
| Adocia SA | 1.38 Million EUR | 202.476% |
| Aelis Farma SA | 12.35 Million EUR | 111.485% |
| Biophytis S.A. | -803 Thousand EUR | -76.748% |
| Advicenne S.A. | 1.42 Million EUR | 199.529% |
| genOway Société anonyme | 20.1 Million EUR | 107.061% |
| IntegraGen SA | 5.01 Million EUR | 128.282% |
| Medesis Pharma S.A. | -2.66 Million EUR | 46.739% |
| Neovacs S.A. | 29.31 Thousand EUR | 4941.676% |
| NFL Biosciences SA | -56.06 Thousand EUR | -2431.551% |
| Plant Advanced Technologies SA | 2.15 Million EUR | 165.924% |
| Sensorion SA | 3.78 Million EUR | 137.469% |
| Theranexus Société Anonyme | -4.63 Million EUR | 69.403% |
| TME Pharma N.V. | -127 Thousand EUR | -1017.55% |
| Valbiotis SA | 2.66 Million EUR | 153.197% |
| TheraVet SA | -530.79 Thousand EUR | -167.389% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | 212.02% |
| DBV Technologies S.A. | 4.15 Million EUR | 134.121% |
| Genfit S.A. | 28.22 Million EUR | 105.029% |
| GeNeuro SA | -293.8 Thousand EUR | -383.08% |
| Innate Pharma S.A. | -4.12 Million EUR | 65.56% |
| Inventiva S.A. | 17.5 Million EUR | 108.11% |
| MaaT Pharma SA | 1.65 Million EUR | 185.758% |
| MedinCell S.A. | 9.28 Million EUR | 115.281% |
| Nanobiotix S.A. | 36.2 Million EUR | 103.92% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 163.731% |
| Poxel S.A. | 1000.00 EUR | 142028.9% |
| GenSight Biologics S.A. | 3 Million EUR | 147.31% |
| Transgene SA | -28.4 Million EUR | 95.003% |
| Valneva SE | 52.83 Million EUR | 102.686% |